Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, orthopedic devices giant Stryker (NYS: SYK) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Stryker's business and see what CAPS investors are saying about the stock right now.
Kalamazoo, Mich. (1941)
Health care equipment
Interim CEO/CFO Curt Hartman
Return on Equity (average, past 3 years)
$3.5 billion / $1.8 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 1,483 members who have rated Stryker believe the stock will outperform the S&P 500 going forward.
Stryker is like my #1 pick for the medical products industry. This company has made money forever and will no doubt in my mind continue to do so. ... 10% growth over the next 5 years. Return on capital of 16% on average over the last five years. Don't stop there look at the last 20. ... Long history and a good track record in the health care industry.
If you want market-topping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Stryker may not be your top choice.
If that's the case, we've compiled a special free report for investors called "The 3 Dow Stocks Dividend Investors Need," which uncovers a few other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow theTrackPoisedToCAPS account.
The article 5-Star Stocks Poised to Pop: Stryker originally appeared on Fool.com.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Stryker. Motley Fool newsletter services have also recommended creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.